Cargando…

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis

INTRODUCTION: Clinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outcomes and the effect of single-inhaler triple versu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, MeiLan K., Criner, Gerard J., Dransfield, Mark T., Halpin, David M.G., Jones, Christine E., Kilbride, Sally, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Wise, Robert A., Naya, Ian P., Singh, Dave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938047/ https://www.ncbi.nlm.nih.gov/pubmed/33718490 http://dx.doi.org/10.1183/23120541.00663-2020

Ejemplares similares

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
por: Singh, Dave, et al.
Publicado: (2016)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

From GOLD 0 to Pre-COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

Diagnosing COPD
por: Halpin, David MG
Publicado: (2006)

Long-term outcomes following first short-term clinically important deterioration in COPD
por: Naya, Ian P., et al.
Publicado: (2018)

Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
por: Lipson, David A., et al.
Publicado: (2021)

ABCD of the phosphodiesterase family: interaction and differential activity in COPD
por: Halpin, David MG
Publicado: (2008)

COPD & COVID-19
por: Halpin, David M.G., et al.
Publicado: (2021)

COPD & COVID-19
por: Halpin, David M.G., et al.
Publicado: (2021)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
por: Kato, Motokazu, et al.
Publicado: (2019)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
por: Kreindler, James L, et al.
Publicado: (2016)

Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials
por: Rubin, David B, et al.
Publicado: (2018)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
por: Marín, José M., et al.
Publicado: (2020)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2prlim7p0upj275vdfrt4m3g22